Antivascular therapy

Phase 3Small molecule

FFudan University

Antivascular therapy is one of 24 small molecule programs targeting Adjuvant Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adjuvant TherapyRecruiting

Adjuvant TherapyPhase 3

Recruiting

Competition

Competitive Landscape

25 competitors in Adjuvant Therapy

#DrugCompanyPhaseTrials

Verzenio

Eli Lilly

Phase 3

1 2

Cialis

Eli Lilly

Phase 3

1 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 4

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 3

2 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 6

Ensacove

XXcovery Holdings, Inc.

Phase 3

1 7

Herceptin

OOrganon and Co

Phase 3

1 8

Beyfortus

BeiGene

Phase 2

2 9

Imfinzi

AstraZeneca

Phase 2

2 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Adjuvant Therapy

NCT05909332

Clinical

Trials by Indication[1]

Adjuvant Therapy1 trial

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Recruiting·FFudan University·Phase 3·NCT05909332·764 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antivascular therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antivascular therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antivascular therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

Antivascular therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Adjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News